Proteomic Profiling as a Diagnostic Biomarker for Discriminating Between Bipolar and Unipolar Depression.

affective disorder biomarker bipolar disorder blood machine learning major depression (MD) major depressive disorder (MDD) proteome

Journal

Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006

Informations de publication

Date de publication:
2020
Historique:
received: 06 12 2019
accepted: 26 02 2020
entrez: 7 5 2020
pubmed: 7 5 2020
medline: 7 5 2020
Statut: epublish

Résumé

Affective disorders are a major global burden, with approximately 15% of people worldwide suffering from some form of affective disorder. In patients experiencing their first depressive episode, in most cases it cannot be distinguished whether this is due to bipolar disorder (BD) or major depressive disorder (MDD). Valid fluid biomarkers able to discriminate between the two disorders in a clinical setting are not yet available. Seventy depressed patients suffering from BD (bipolar I and II subtypes) and 42 patients with major MDD were recruited and blood samples were taken for proteomic analyses after 8 h fasting. Proteomic profiles were analyzed using the Multiplex Immunoassay platform from Myriad Rules Based Medicine (Myriad RBM; Austin, Texas, USA). Human DiscoveryMAP Based on the various proteomic profiles, the algorithm could discriminate depressed BD patients from MDD patients with an accuracy of 67%. The results of this preliminary study suggest that future discrimination between bipolar and unipolar depression in a single case could be possible, using predictive biomarker models based on blood proteomic profiling.

Identifiants

pubmed: 32372978
doi: 10.3389/fpsyt.2020.00189
pmc: PMC7184109
doi:

Types de publication

Journal Article

Langues

eng

Pagination

189

Informations de copyright

Copyright © 2020 Kittel-Schneider, Hahn, Haenisch, McNeill, Reif and Bahn.

Références

Exp Neurobiol. 2014 Mar;23(1):28-35
pubmed: 24737937
Neuroimage. 2017 Jan 15;145(Pt B):254-264
pubmed: 26883067
Bipolar Disord. 2015 May;17(3):269-77
pubmed: 25257835
Biol Psychol. 2008 Oct;79(2):256-9
pubmed: 18644422
Schizophr Bull. 2004;30(4):923-34
pubmed: 15954198
Br J Psychiatry. 2011 Aug;199(2):151-5
pubmed: 21804150
Cell. 2019 May 16;177(5):1280-1292.e20
pubmed: 31031006
Psychopharmacology (Berl). 2006 Dec;189(2):225-35
pubmed: 17016711
J Neuroimmune Pharmacol. 2016 Jun;11(2):248-58
pubmed: 27108110
J Proteome Res. 2015 Aug 7;14(8):3382-9
pubmed: 26168936
Pharmacoeconomics. 2015 Apr;33(4):341-53
pubmed: 25576148
Psychoneuroendocrinology. 2017 Jan;75:72-82
pubmed: 27810706
J Biol Chem. 1999 Oct 22;274(43):30617-23
pubmed: 10521446
J Psychopharmacol. 2015 Jan;29(1):31-8
pubmed: 25320160
Ann Clin Biochem. 2016 Sep;53(Pt 5):606-10
pubmed: 26748102
JAMA Psychiatry. 2013 Jan;70(1):31-41
pubmed: 22945416
Schweiz Arch Neurol Psychiatr (1985). 1988;139(2):51-65
pubmed: 2455937
Bipolar Disord. 2009 May;11(3):225-55
pubmed: 19419382
Neuropsychiatr. 2011;25(1):16-25
pubmed: 21486540
PLoS One. 2015 Nov 18;10(11):e0143397
pubmed: 26581044
Anticancer Res. 2016 Oct;36(10):5079-5086
pubmed: 27798867
BMC Urol. 2012 Aug 16;12:21
pubmed: 22898175
Biol Psychiatry. 2019 Nov 1;:
pubmed: 31926635
Z Psychosom Med Psychother. 2010;56(4):334-42
pubmed: 21243603
J Clin Psychiatry. 2009 Aug;70(8):1078-90
pubmed: 19497250
J Psychiatry Neurosci. 2015 Sep;40(5):316-24
pubmed: 25853284
J Affect Disord. 2012 Oct;140(2):181-6
pubmed: 22397888
Mol Psychiatry. 2006 Mar;11(3):286-300
pubmed: 16389274
Bipolar Disord. 2006 Feb;8(1):85-90
pubmed: 16411985
J Affect Disord. 2014 Mar;157:87-91
pubmed: 24581833
Br J Psychiatry. 2012 Jan;200(1):45-51
pubmed: 22016435
J Affect Disord. 2016 Sep 15;202:1-9
pubmed: 27253210
Neuropsychopharmacol Rep. 2020 Mar;40(1):39-45
pubmed: 31774942
J Vasc Surg. 2012 Apr;55(4):1096-1103.e51
pubmed: 22100532
Brain Behav Immun. 2016 Feb;52:49-57
pubmed: 26441135
Cell. 2005 Feb 11;120(3):421-33
pubmed: 15707899
Eur Arch Psychiatry Clin Neurosci. 2020 Mar;270(2):169-181
pubmed: 30929061
Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jan 3;48:236-44
pubmed: 24121060
Psychoneuroendocrinology. 2008 Jun;33(5):612-24
pubmed: 18329819
Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2872-81
pubmed: 18843033
Transl Psychiatry. 2015 Dec 08;5:e689
pubmed: 26645624
J Psychopharmacol. 2009 Jun;23(4):346-88
pubmed: 19329543

Auteurs

Sarah Kittel-Schneider (S)

Department of Psychiatry, Psychotherapy and Psychosomatic Medicine, University Hospital, University of Würzburg, Würzburg, Germany.
Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital, Goethe-University of Frankfurt, Frankfurt, Germany.

Tim Hahn (T)

Department of Psychiatry, Psychotherapy and Psychosomatic Medicine, University Hospital, University of Münster, Münster, Germany.

Frieder Haenisch (F)

Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, United Kingdom.

Rhiannon McNeill (R)

Department of Psychiatry, Psychotherapy and Psychosomatic Medicine, University Hospital, University of Würzburg, Würzburg, Germany.

Andreas Reif (A)

Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital, Goethe-University of Frankfurt, Frankfurt, Germany.

Sabine Bahn (S)

Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, United Kingdom.

Classifications MeSH